Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension: a Multicentre Prospective Randomized Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07470580
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:13.526598+00:00
Published At
2026-03-13T00:00:00+00:00
Record Updated At
2026-03-13
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Primary Aldosteronism Due to Conn Adenoma", "Radiofrequency Ablation Treatment", "Adrenalectomy"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-03-13"
protocolSection.identificationModule.nctId
"NCT07470580"
protocolSection.identificationModule.officialTitle
"Radiofrequency Ablation Versus Adrenalectomy for Adenoma in Patients With Primary Aldosteronism and Hypertension: a Multicentre Prospective Randomized Study"
protocolSection.statusModule.overallStatus
"NOT_YET_RECRUITING"
protocolSection.designModule.phases
["NA"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Primary Aldosteronism Due to Conn Adenoma (protocolSection.conditionsModule.conditions)
  • Radiofrequency Ablation Treatment (protocolSection.conditionsModule.conditions)
  • Adrenalectomy (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.